North America Biosimilars Market Size & Outlook, 2020-2027
North America biosimilars market, 2016-2027 (US$M)
Related Markets
North America biosimilars market highlights
- The North America biosimilars market generated a revenue of USD 3,389.9 million in 2020.
- The market is expected to grow at a CAGR of 26.1% from 2021 to 2027.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2020.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2021 to 2027.
North America data book summary
| Market revenue in 2020 | USD 3,389.9 million |
| Market revenue in 2027 | USD 17,204.5 million |
| Growth rate | 26.1% (CAGR from 2020 to 2027) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data covered | 2016 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 25.6% of the global biosimilars market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2027.
- North America is the fastest growing regional market and is projected to reach USD 17,204.5 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 54.79% in 2020. Horizon Databook has segmented the North America biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
North America is expected to witness high CAGR during the forecast period, due to rising efforts from manufacturers to tap growth opportunities in U.S. and Canada. The U.S. biosimilar regulatory pathway was established in March 2009, and since then the region has gained significant momentum, presenting new opportunities and challenges.
Rise in the number of approvals is anticipated to boost the adoption of biosimilars in the near future in the region. For instance, in December 2019, Amgen received FDA approval for AVSOLA (infliximabaxxq).
The biosimilar was approved for all the indications of chronic inflammatory conditions. Total healthcare costs have increased due to high-prices patented pharmaceutical drugs, especially biologics.
Reasons to subscribe to North America biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America biosimilars market , including forecasts for subscribers. This continent databook contains high-level insights into North America biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
North America biosimilars market size, by country, 2016-2027 (US$M)
North America Biosimilars Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
